Keane Butts

Keane Butts serves as a key procurement professional within the Administration for Strategic Preparedness and Response (ASPR), supporting the agency’s mission to ensure national readiness for public health emergencies through the acquisition of critical biomedical and scientific capabilities. Responsible for managing research and development contracts, Butts facilitates the procurement of advanced medical countermeasures, diagnostic platforms, and laboratory infrastructure essential to rapid response against pandemics, chemical threats, and biological incidents. Their work directly enables the agency’s strategic objective of sustaining a resilient biomedical industrial base by accelerating the transition of scientific innovations from concept to operational deployment. Butts maintains a broad network of contractor relationships with leading research institutions, biotech firms, and engineering service providers specializing in life sciences R&D. While no single vendor dominates the portfolio, the procurement pattern reflects a preference for established scientific contractors with proven capacity in high-containment laboratory operations, assay development, and rapid-scale manufacturing readiness. Relationships are typically performance-driven, emphasizing technical rigor, regulatory compliance, and agile delivery timelines aligned with emergency response timelines. Butts consistently awards contracts under the “No Set-Aside” category, indicating a focus on technical capability and mission urgency over socioeconomic preferences. This reflects the agency’s prioritization of speed and scientific excellence during public health emergencies, where the availability of specialized expertise outweighs traditional small business set-aside criteria. While socioeconomic programs are not actively leveraged, compliance with all federal contracting regulations remains strictly observed. The primary NAICS classification for Butts’ portfolio is 541715, encompassing research and development in the physical, engineering, and life sciences. This specialization drives the acquisition of advanced laboratory systems, biosafety equipment, diagnostic assay validation services, and computational modeling tools. Their technical domain expertise centers on translational biomedical research, with a focus on scalable, regulatory-ready solutions that bridge the gap between academic innovation and federal operational needs.